Treatment of chronic stable angina with carvedilol: A multiple-action neurohormonal antagonist. A review of controlled clinical trials

Journal of International Medical Research

Volumn 26, Issue 3, 1998, Pages 107-119

  Gonzalez Maqueda I ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Regional Government   (Spain)

Author keywords

Alpha blockade; Beta blockade; Carvedilol; Chronic stable angina pectoris; Multiple action neurohormonal antagonist

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CATECHOLAMINE; DOXAZOSIN; ISOSORBIDE DINITRATE; NEUROHORMONE; NIFEDIPINE; NITRATE; OXYGEN RADICAL; PROPRANOLOL; SCAVENGER; VERAPAMIL;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANGINA PECTORIS; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BETA ADRENERGIC RECEPTOR BLOCKING; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ERYTHROCYTE AGGREGATION; FLUSHING; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PALPITATION; HUMAN; HYPOTENSION; LIPID BLOOD LEVEL; PLASMA VISCOSITY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE; VERTIGO;

EID: 0031878751     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059802600301     Document Type: Review

References (50)

1. Mann JI, Marmot MG: Epidemiology of Ischaemic Heart Disease. In: Oxford Textbook of Medicine, 2nd Edn (Weatherall DJ, Ledingham JGG, Worell DA, eds) Oxford: Oxford University Press, 1986; pp13.143-13.154.
2. Gersh BJ, Braunwald E, Rutherford JD: Chronic coronary artery disease. In: Heart Disease: a Textbook of Cardiovascular Medicine, 5th Edn (Braunwald E, ed). Philadelphia: WB Saunders, 1997; pp1289-1366.
3. Matthews MB, Julian DE: Angina pectoris. Definition and description. In: Angina Pectoris, 2nd Edn (Julian DG, ed). New York: Churchill Livingstone, 1985; p2.
4. Levy D, Anderson KM, Savage DD, et al: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13.
5. Frishman WH: Pharmacology of the nitrates in angina pectoris. Am J Cardiol 1985; 56: 81-131.
6. Furchgott RF, Zawadski JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
7. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
8. Mangione NJ, Glasser SP: Phenomenon of nitrate tolerance. Am Heart J 1994; 128: 137-146.
9. Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med 1995; 155: 357-364.
10. Opie LH: Calcium channel antagonists, Part 1: Fundamental properties: mechanisms, classification, sites of action. Cardiovasc Drugs Ther 1987; 1: 411-430.
11. Robertson RM, Robertson D: Drugs used for the treatment of myocardial ischaemia. In: The Pharmacological Basis of Therapeutics, 9th Edn (Hardman JG, Gilman AG, Limbird LE, eds). New York: McGraw-Hill, 1996; pp759-779.
12. Watanabe AM: Recent advanes in knowledge about beta-adrenergic receptors: application to clinical cardiology. J Am Coll Cardiol 1993; 1: 82-89.
13. Prichard BNC: Beta-adrenergic receptor blocking agents in angina pectoris. Drugs 1974; 7: 55-84
14. Opie LH: Basics for cardiovascular therapy with beta-blocking agents. Am J Cardiol 1983; 52: 2D-9D.
15. Roberts R, Croft C, Gold HK, et al: Effect of propranolol on myocardial infarct size in a randomised blinded multicenter trial. New Engl J Med 1984; 311: 218-250.
16. Pedersen TR and the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction: Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New Engl J Med 1985; 313: 1055-1056.
17. Hjalmarson A, Herlitz J, Malek I, et al: Effect on mortality of metoprolol after acute myocardial infarction. Lancet 1981; 2: 823-827.
18. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-371.
19. Dahlöf B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
20. Hoffman BB, Lefkowitz RJ: Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: The Pharmacological Basis of Therapeutics, 9th Edn (Hardman JG, Gilman AG, Limbird LE, eds). New York: McGraw-Hill, 1996; pp199-248.
21. Rodrigues EA, Lahiri A, Hughes LO, et al: Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity. Am J Cardiol 1986; 58: 916-921.
22. Lahiri A, Rodrigues EA, DasGupta P, et al: Effects of carvedilol in patients with left ventricular function due to ischaemic heart disease. Zeitschr Kardiol 1989; 78(Suppl): 21-27.
23. Lahiri A, Rodrigues EA, Al-Khawaja I, Raftery EB: Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. Am J Cardiol 1987; 59: 769-774.
24. Lahiri A, Rodrigues EA, Heber ME, et al: Effects of carvedilol on left ventricular function in essential hypertension and ischaemic heart disease. Drugs 1988; 36(Suppl 6): 141-143.
25. Francis GS, Cohn JN, Johnson G, et al: Plasma norepinephrine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II follow-up. Circulation 1993; 83(Suppl VI): VI40-VI48.
26. Basu S, Senior R, Raval U, et al: Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled randomized trial. Circulation 1997; 96: 183-191.
27. 1 in non-insulin-dependent diabetics. Drugs 1988; 36: 136-140.
28. Jacob S, Rett K, Wickmayr M, et al: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprol study. J Hypertens 1996; 14: 489-494.
29. González Maqueda I: Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994; 5: 909-918.
30. Hauf-Zachariou U, Widmann L, Zülsdorf B, et al: A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993; 45: 95-100.
31. Wendt T, van der Does R, Schräder R, et al: Acute hemodynamic effects of the vasodilating and β-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol 1987; 10(Suppl 11): 147-150.
32. Sung C-P, Arleth AJ, Ohlstein EH: Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21: 221-227.
33. Yue T-L, Liu T, Feverstein G: Carvedilol, a new vasodilator and beta-adrenoreceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992; 1: 27-35.
34. Downey JM: Free radicals and other involvement during long-term myocardial ischaemia and reperfusion. Ann Rev Physiol 1990; 52: 487-504.
35. Yue T-L, Cheng H-Y, Lysko PG, et al: Carvedilol, a new vasodilator and beta-adrenoreceptor antagonist, is an anti-oxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-98.
36. Maggi E, Marchesi E, Covini D, et al: Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996; 27: 532-538.
37. Gasser JA, Betterridge DJ: Comparison of the effects of carvedilol, propranolol and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol 1991; 18(Suppl 4): 29-34.
38. Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A: Efficacy of carvedilol (BM14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol 1985; 56: 35-40.
39. DasGupta P, Jain D, Lahiri A, Raftery EB: Long-term efficacy and safety of carvedilol, a new β-blocking agent with vasodilating properties, in patients with chronic ischaemic heart disease. Drug Invest 1992; 4: 263-272.
40. Jamal SM, Freedman SB, Thomson A, et al: Anti-anginal efficacy of carvedilol, a new β-blocker with vasodilating action. J Cardiovasc Pharmacol 1987; 10(Suppl): 141-146.
41. Kishida H, Saito T, Fukuma N, et al: Evaluation of a new vasodilating β-blocking agent, carvedilol, in exertional angina using Holter monitoring. Jpn Heart J 1990; 31: 449-460.
42. Rodrigues EA, Hains ABD, Lahiri A, et al: Effects of combined beta-blockage and calcium antagonists on myocardial ischaemia and ventricular function in stable angina. Clin Sci 1988; 75: 4P.
43. Rodrigues EA, Lawrence JD, Dasgupta P, et al: Comparison of bevantalol and atenolol in chronic stable angina. Am J Cardiol 1988; 61: 1204-1209.
44. Garnham SP, Gunawardena K, Hauf-Zachariou U, Blackwood RA: Carvedilol in chronic stable angina. Clin Pharmacol Ther 1995; 59: 163.
45. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al: Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997; 52: 95-100.
46. van der Does R, Eberhardt R, Derr I, et al: Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. Eur Heart J 1991; 12: 60-64.
47. van der Does R, Eberhardt R, Derr I, Ehmer B: Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. J Cardiovasc Pharmacol 1992; 19(Suppl): 122-127.
48. Nahrendorf W, Rading A, Steinig G, et al: A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina. J Cardiovasc Pharmacol 1992; 19(Suppl 1): 114-116.
49. Freedman SB, Jamal SM, Harris PJ, Kelly DT: Comparison of carvedilol and atenolol for angina pectoris. Am J Cardiol 1987; 60: 499-502.
50. Hauf-Zachariou U, Pfarr E, van der Does R: Carvedilol in comparison and in combination with isosorbide dinitrate sustained in patients with chronic stable effort-induced angina pectoris. Clin Drug Invest 1997; 14: 465-473.